INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma

Abstract Background Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–drug conjugate consisting of an antibody (ABT-806) directed against activated epidermal growth factor receptor (EGFR) and the toxin monomethylauristatin-F. We investigated Depatux-M in combination with temozolomide...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2020-05, Vol.22 (5), p.684-693
Hauptverfasser:	Van Den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Smits, Marion, Walenkamp, Annemiek, Frenel, Jean-Sebastian, Franceschi, Enrico, Clement, Paul M, Chinot, Olivier, De Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Weller, Michael, Dubbink, H J, French, Pim, Looman, Jim, Dey, Jyotirmoy, Krause, Scott, Ansell, Pete, Nuyens, Sarah, Spruyt, Maarten, Brilhante, Joana, Coens, Corneel, Gorlia, Thierry, Golfinopoulos, Vassilis
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized Antineoplastic Agents, Alkylating - therapeutic use Brain Neoplasms - drug therapy Clinical Investigations Editor's Choice ErbB Receptors - genetics Glioblastoma - drug therapy Humans Lomustine - therapeutic use Temozolomide - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!